Heres my analysis: Asterias Biotherepeautics stem cell treatment can allow quadripelegics to regain use of their upper bodies. There are ~12000 spinal cord injuries in the USA each year, ~50% are quadripelegic. Thats 6000 people who should be getting treated a year. Im gonna assume this treatment is gonna cost 20k, thats 120 million in revenue every year. Id hope the company could work at a 40% operating margins, so 48 million in profit from this treatment every year. at 20x earnings the market cap should be 960 million. Market cap today is less than 150 million. . . what do you think?
Submitted August 21, 2017 at 02:30PM by throwawayquartermill http://ift.tt/2x6cvQv
